Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio
09/03/2026 11:04
March 9 (Reuters) - Protalix Biotherapeutics Inc PBDA.F: CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS ANNOUNCE EUROPEAN COMMISSION APPROVAL OF ADDITIONAL DOSING REGIMEN OF EVERY FOUR WEEKS FOR ELFABRIO® (PEGUNIGALSIDASE ALFA) PROTALIX BIOTHERAPEUTICS INC - ENTITLED TO $25 MILLION REGULATORY MILESTONE PAYMENT FROM CHIESI FOR EC'S APPROVAL OF E4W DOSING REGIMEN Source text: ID:nGNX7NF14L Further company coverage: PBDA.F ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protalix Biotherapeutics
See all newsIsrael's Protalix Q1 revenue surges on Chiesi milestone
Brief: Protalix BioTherapeutics Q1 EPS USD 0.23
Brief: Protalix Biotherapeutics Reports Fiscal Year 2025 Financial And Business Results
Brief: EU Approves Four‑week Dosing Option For Chiesi and Protalix’s Elfabrio
Brief: Protalix Biotherapeutics And Secarna Pharmaceuticals Enter Into Collaboration And Option Agreement